GlobeNewswire Inc | Jul 26, 2021 04:30PM EDT

July 26, 2021

Montrouge, France, July 26, 2021

DBV Technologies to Report First Half 2021 Financial Results and Business Updates on August 2, 2021

DBV Technologies (Euronext: DBV ISIN: FR0010417345 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Monday, August 2, 2021, at 5:00 p.m. ET to report first half 2021 financial results and provide a corporate update.

This call is accessible via the below teleconferencing numbers, followed by the reference ID: 50184237.United States: (866)-939-3921

Canada: (866)-215-5508United Kingdom: 0808 238 9578

France: 0805 102 604

A live webcast of the call will be available on the Investors & Media section of the Companys website: https://www.dbv-technologies.com/investor-relations/. A replay of the presentation will also be available on DBVs website after the event.

About DBV TechnologiesDBV Technologies is developing Viaskin, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT, DBVs method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBVs food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France, and North American operations in Summit, NJ. The Companys ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Companys ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).

Investor Contact Anne PollakDBV Technologies+1 857-529-2363anne.pollak@dbv-technologies.com

Media ContactAngela MarcucciDBV Technologies+1646-842-2393angela.marcucci@dbv-technologies.com

Attachment

-- PDF Version